US rejects WHO pandemic changes to global health rules
By Ahmed Aboulenein
WASHINGTON (Reuters) -The United States has rejected amendments adopted in 2024 by members of the World Health Organization to its legally binding health rules aimed at improving preparedness for future pandemics following the disjointed global response to COVID-19.
The Department of State and Department of Health and Human Services said in a statement they had transmitted on Friday the official U.S. rejection of the amendments to the International Health Regulations, which were adopted by consensus last year.
The amendments introduced a new category of "pandemic emergency" for the most significant and globally threatening health crises in an effort to shore up the world's defenses against new pathogens.
"Developed without adequate public input, these amendments expand the role of the WHO in public health emergencies, create additional authorities for the WHO for shaping pandemic declarations, and promote WHO's ability to facilitate 'equitable access' of health commodities," the U.S. statement said.
"Terminology throughout the 2024 amendments is vague and broad, risking WHO-coordinated international responses that focus on political issues like solidarity, rather than rapid and effective actions," said the statement, jointly issued by Secretary of State Marco Rubio and Secretary of Health and Human Services Robert F. Kennedy Jr.
Kennedy, who has a long history of sowing doubt about vaccine safety, had slammed the WHO in a video address to the Assembly during its vote on a separate pandemic agreement, saying it had failed to learn from the lessons of the pandemic.
That pact, which was adopted in Geneva in May after three years of negotiations, aims to ensure that drugs, therapeutics and vaccines are globally accessible when the next pandemic hits. It requires participating manufacturers to allocate a target of 20% of their vaccines, medicines and tests to the WHO during a pandemic to ensure poorer countries have access.
U.S. negotiators left discussions about the accord after President Donald Trump began a 12-month process of withdrawing the U.S. - by far the WHO's largest financial backer - from the agency when he took office in January. Its exit means the U.S. would not be bound by the pact.
Kennedy and Rubio said on Friday that their rejection protects U.S. sovereignty. The IHR amendments and the parallel pandemic pact leave health policy to national governments and contain nothing that overrides national sovereignty, however.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Cutting-edge Diagnostic Technologies Transforming $6.4 Billion Landscape
The U.S. Alzheimer's disease diagnostics market, valued at USD 3.53 billion in 2024, is projected to grow at a CAGR of 10.6% from 2025-2030. Growth is driven by rising Alzheimer's prevalence and advanced diagnostics like FDA-approved blood tests, improving early detection and care planning. U.S. Alzheimer's Disease Diagnostics Market Dublin, July 28, 2025 (GLOBE NEWSWIRE) -- The "U.S. Alzheimer's Disease Diagnostics Market Size, Share & Trends Analysis Report By Diagnostic Technique (Biomarkers, Imaging Techniques, Genetic Testing, Cognitive Assessment Tests), By Type, By End-use, And Segment Forecasts, 2025 - 2030" report has been added to U.S. Alzheimer's disease diagnostics market was valued at USD 3.53 billion in 2024 and is expected to grow at a CAGR of 10.6% from 2025 to 2030 This growth is driven by the rising prevalence of Alzheimer's disease and increasing emphasis on early and accurate diagnosis. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 6.7 million older adults in the U.S. were living with Alzheimer's disease in 2024, a number projected to nearly double by 2060. The growing prevalence of the disease prompted government and private healthcare bodies to invest heavily in advanced diagnostic technologies such as PET imaging, cerebrospinal fluid biomarkers, and blood-based diagnostics. The growth of the U.S. Alzheimer's disease diagnostics market is due to the recent regulatory approval of advanced, non-invasive diagnostic technologies. The U.S. FDA granted marketing clearance for the first in vitro diagnostic device that utilizes a blood test to support the diagnosis of Alzheimer's disease. The Lumipulse G pTau217/b-Amyloid 1-42 Plasma Ratio is specifically intended for the early detection of amyloid plaque accumulation, a hallmark of Alzheimer's pathology, in adult patients aged 55 years and older who are exhibiting clinical signs and symptoms consistent with cognitive development represents a major advancement in Alzheimer's diagnostics, significantly lowering access barriers by providing a cost-effective and minimally invasive alternative to PET scans and lumbar punctures, which often carry procedural risks. The FDA highlighted that this approval makes it easier and potentially more accessible for U.S. patients earlier in the disease. It underscores the test's value in facilitating timely intervention and clinical decision-making in the early stages of Alzheimer's disease increasing rate of dementia diagnosis among older adults is driving the growth of the U.S. Alzheimer's diagnostics market. According to the 2022 National Health Interview Survey by the CDC, approximately 4% of individuals aged 65 and older have been diagnosed with dementia, with this figure rising to 13% among those aged 85 and above. This growth is primarily attributed to longer life expectancy, enhanced awareness, and improved diagnostic practices across clinical settings. The rising need for scalable, accurate diagnostic solutions to support early detection, appropriate intervention, and optimized care planning. Why should you buy this report? Comprehensive Market Analysis: Gain detailed insights into the global market across major regions and segments. Competitive Landscape: Explore the market presence of key players worldwide. Future Trends: Discover the pivotal trends and drivers shaping the future of the global market. Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions. Key Attributes: Report Attribute Details No. of Pages 80 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $3.53 Billion Forecasted Market Value (USD) by 2030 $6.43 Billion Compound Annual Growth Rate 10.6% Regions Covered United States Competitive Landscape GE HealthCare Siemens Healthineers AG Canon Medical Systems Corporation Cerveau Technologies, Inc. Neurovision Imaging, Inc. Thermo Fisher Scientific Inc. Bio-Rad Laboratories, Inc. Quanterix Corporation Alzheon Inc. NanoSomiX, Inc. DiamiR Biosciences Company Overview Financial Performance Diagnostic Technique Portfolio Recent Developments/ Strategic Initiatives U.S. Alzheimer's Disease Diagnostics Market Report SegmentationDiagnostic Technique Outlook (Revenue, USD Million, 2018 - 2030) Biomarkers CSF Biomarkers Blood-Based Biomarkers Imaging Diagnostic Techniques Genetic Testing Cognitive Assessment Tests Type Outlook (Revenue, USD Million, 2018 - 2030) Triage Diagnosis Screening End Use Outlook (Revenue, USD Million, 2018 - 2030) Hospitals Diagnostic Laboratories Academic & Research Institutes For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment U.S. Alzheimer's Disease Diagnostics Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio


Fox News
4 minutes ago
- Fox News
Stephen A Smith calls out 'leaderless' Democrats amid party's record-low polling
Attorney Mehek Cooke on the Democratic Party's record-low polling, the work Republicans need to do to deliver promises to the American people and Jay Leno's criticism of late-night comedians for alienating half of their audience with politics.


Fox News
4 minutes ago
- Fox News
Former CBS anchor warns Paramount merger marks 'the end' of the network and 'honest' journalism
Former CBS anchor Connie Chung warned on CNN Friday that the recent merger between Paramount Global and Skydance Media could be the "end" of journalism as she once knew it. The FCC announced it approved an $8 billion merger between the two companies on Thursday with the deal set to close on August 7. This came after several controversies involving CBS, which Paramount owns, such as a lawsuit settlement with President Donald Trump over a "60 Minutes" segment and canceling "The Late Show with Stephen Colbert." Based on the newly formed company Paramount Skydance Corp., the former "CBS Evening News" anchor suggested the network she was a part of could lose all of its independence. "I fear the end of CBS as I knew it," Chung said on "CNN News Central." "CBS was always a standalone network. It was autonomous. The news division was autonomous, and it was always unencumbered by pressures from politicians, including presidents, and unencumbered by bean counters. But now? I can see very clearly that the days that I remembered are long gone." She continued, "Honest, unbiased, fact-based journalism is being tainted and those who practiced that journalism, like Edward R. Murrow and Walter Cronkite, that kind of journalism has disappeared. I also fear that gone are the days of Frank Stanton, who was the president of CBS, who defended the rights of the journalism, the First Amendment, the fourth estate before Congress, and he represented all journalists in many ways." Chung placed more blame on Paramount's controlling shareholder Shari Redstone and Skydance Media CEO David Ellison for having "tainted journalism" with their "greed." She also called out company's pledge to not implement any new DEI initiatives as an insult to her and other women and minorities at CBS. Several journalists have accused CBS and Paramount of acquiescing to Trump ahead of the merger through its settlement and cancellations, including Chung. "I have difficulty believing what they claim, which is that the '60 Minutes' agreement had nothing to do with the merger, or a settlement had nothing to do with the merger, and also that the disappearance of Steve [sic] Colbert had nothing to do — it had only to do with financial issues. It all smells," Chung said. Paramount has been facing an intense backlash for its recent decisions, even from some of its own employees. Veteran "60 Minutes" producer Rome Hartman told Fox News Digital earlier this month that he thought the company's settlement with Trump was a "cowardly capitulation by the corporate leaders of Paramount" and a "fundamental betrayal" of CBS News. Senators Bernie Sanders, I-Vt., Elizabeth Warren, D-Mass. and Ron Wyden, D-Ore., also sent a letter to Ellison demanding answers about the Trump settlement and the Colbert cancellation, suggesting anti-bribery laws may have been broken in order for the merger to proceed with FCC approval.